Skip to main content
padlock icon - secure page this page is secure

Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia

Buy Article:

$59.00 + tax (Refund Policy)

Abstract

Objectives:  Waldenstrom Macroglobulinemia (WM) is a B‐cell neoplasm characterised by secretion of IgM by lymphoplasmacytic bone marrow cells and by cytopenias and hypogammaglobulinemia in a subset of patients. Beta‐2 microglobulin (b2m) is a major prognostic factor in WM and the heavy chain of HLA class I molecules, which are known to have immunosuppressive properties and have been implicated in the pathogeny of several malignancies.

Methods:  We assessed the serum levels of the total soluble HLA‐I molecules and the HLA‐Gs molecules in 105 patients with IgM‐related disorders [WM (n = 42) and IgM MGUS (n = 63)], and compared the results to 41 healthy subjects.

Results:  We found higher levels of HLA‐Is in WM, compared to IgM MGUS and healthy donors. HLA‐Gs levels were similar in WM and in IgM MGUS, but higher than in healthy donors. The association between HLA‐Is at the cut‐off of 1.8 μg/mL and known markers of poor prognosis was then evaluated among WM patients using univariate and multivariate methods. Based on this, high HLA‐Is level was strongly associated with high serum β2M level >3 mg/L [OR = 2, (CI 95% 1.1–5.7); P = 0.04], age > 65 yrs [OR = 1.5, (CI 95% 0.5–4.1), P = 0.06] and haemoglobin ≤11.5 g/dL [OR = 3.3, (CI 95% 1.2–9.7); P = 0.03]. High levels of serum HLA‐Is were also found in patients with cryoglobulinemia, however irrespectively of WM or IgM‐MGUS status.

Conclusion:  Together our results suggest a possible role for soluble MHC class I molecules in WM disease. Further investigations are necessary to further demonstrate the prognostic impact of soluble MHC class I molecules in Waldenstrom Macroglobulinemia.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Laboratoire d’Hématologie et d’Immunologie, UPRES 38-89, CHU, Rennes, France 2: Laboratoire de Biostatistique et Biomathématiques, CHRU, Lille, France 3: Department of Medical oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA 4: Service des Maladies du Sang, CHRU, Lille, France 5: Laboratoire de Biologie Moleculaire, CH, Valenciennes, France 6: Laboratoire de Biochimie, CHRU, Lille, France 7: Laboratoire d’Immunologie, CHRU, Lille, France 8: Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA

Publication date: June 1, 2008

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more